Laboratory and clinical studies on cefdinir

Yuei Irabu, Kazunori Tamaki, Hiroshi Fukuhara, Hiroaki Nakamura, Hiroshi Kaneshima, Katsuyoshi Shimoji, Keizou Kitsukawa, Yoshiteru Shigeno, Atsushi Saito, Shinko Taira, Isamu Nakasone, Nobuchika Kusano, Seitetsu Hokama

Research output: Contribution to journalArticlepeer-review

2 Citations (Scopus)


We performed basic and clinical studies on cefdinir (CFDN), a new cephalosporin, with the followings. 1. Antimicrobial activity, concentration in plasma and sputum The minimum inhibitory concentrations (MICs) of CFDN against a total of 348 clinically isolated strains were determined and compared with those of cefaclor, ampicillin, cefteram, cefixime and cefotiam, using the MIC-2000 System (Dynatech Laboratories). CFDN had wide antimicrobial activity against these clinically isolated strains except Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus. The maximum plasma concentration was 0.841μ g/ml, and the maximum sputum concentration was 0.076μg/ml. 2. Clinical efficacy CFDN was given in a daily dose of 300 mg or 600 mg to 1 patient with acute tonsillitis, 1 with acute bronchitis, 5 with chronic bronchitis, 1 with bronchiectasis, 3 with diffuse panbronchiolitis and 2 with bacterial pneumonia for 5-14 days. Clinical response was excellent in 1 patient, good in 9, fair in 2, and poor in 1, the clinical efficacy rate being 77%. Skin eruption as a side effect was observed in one patient. Altered laboratory findings were: 1 case of transient elevation of GPT, 1 of transient elevation of GPT and Al-P, and 1 of increase in eosinophils.

Original languageEnglish
Pages (from-to)603-611
Number of pages9
Publication statusPublished - 1989
Externally publishedYes


  • Cefdinir

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Infectious Diseases
  • Pharmacology
  • Drug Discovery
  • Oncology


Dive into the research topics of 'Laboratory and clinical studies on cefdinir'. Together they form a unique fingerprint.

Cite this